Roth Capital Lifts Earnings Estimates for LeMaitre Vascular

Key Points

• Roth Capital has raised its Q2 2026 EPS estimate for LeMaitre Vascular from $0.62 to $0.63, indicating positive expectations for the company’s earnings performance.
• LeMaitre Vascular's quarterly earnings report revealed an EPS of $0.60, surpassing the consensus estimate of $0.57, alongside a revenue increase of 15% year-over-year.
• The company will distribute a quarterly dividend of $0.20 per share on September 4th, reflecting a dividend yield of 0.8% and a payout ratio of 40.40%.

LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) - Equities researchers at Roth Capital raised their Q2 2026 earnings per share (EPS) estimates for LeMaitre Vascular in a report issued on Tuesday, August 5th. Roth Capital analyst J. Wittes now forecasts that the medical instruments supplier will post earnings of $0.63 per share for the quarter, up from their prior forecast of $0.62. The consensus estimate for LeMaitre Vascular's current full-year earnings is $1.94 per share. Roth Capital also issued estimates for LeMaitre Vascular's Q3 2026 earnings at $0.62 EPS, Q4 2026 earnings at $0.64 EPS, FY2026 earnings at $2.49 EPS and FY2027 earnings at $2.96 EPS.

Other equities analysts also recently issued reports about the company. Cantor Fitzgerald increased their target price on LeMaitre Vascular from $92.00 to $95.00 and gave the stock a "neutral" rating in a research note on Wednesday, August 6th. Barrington Research raised LeMaitre Vascular from a "market perform" rating to an "outperform" rating and set a $95.00 price objective for the company in a research report on Wednesday, August 6th. Four analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to data from MarketBeat.com, LeMaitre Vascular presently has an average rating of "Hold" and a consensus price target of $98.00.

LeMaitre Vascular Stock Performance

Shares of NASDAQ LMAT traded up $0.56 during trading hours on Thursday, reaching $92.84. The stock had a trading volume of 95,999 shares, compared to its average volume of 189,066. LeMaitre Vascular has a fifty-two week low of $71.42 and a fifty-two week high of $109.58. The firm has a 50-day moving average of $83.35 and a 200-day moving average of $86.50. The company has a current ratio of 13.96, a quick ratio of 11.74 and a debt-to-equity ratio of 0.46. The firm has a market cap of $2.10 billion, a price-to-earnings ratio of 44.99, a PEG ratio of 2.37 and a beta of 0.79.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last posted its quarterly earnings data on Tuesday, August 5th. The medical instruments supplier reported $0.60 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.57 by $0.03. The firm had revenue of $63.15 million for the quarter, compared to the consensus estimate of $62.48 million. LeMaitre Vascular had a return on equity of 13.67% and a net margin of 20.08%. The company's quarterly revenue was up 15.0% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.52 EPS.

LeMaitre Vascular Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, September 4th. Investors of record on Thursday, August 21st will be issued a $0.20 dividend. The ex-dividend date of this dividend is Thursday, August 21st. This represents a $0.80 dividend on an annualized basis and a dividend yield of 0.9%. LeMaitre Vascular's dividend payout ratio (DPR) is currently 38.83%.

Insider Buying and Selling at LeMaitre Vascular

In other LeMaitre Vascular news, CEO George W. Lemaitre sold 100,000 shares of LeMaitre Vascular stock in a transaction on Wednesday, August 6th. The shares were sold at an average price of $93.51, for a total value of $9,351,000.00. Following the sale, the chief executive officer directly owned 1,727,003 shares in the company, valued at approximately $161,492,050.53. The trade was a 5.47% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders have sold a total of 200,000 shares of company stock valued at $17,907,857 over the last three months. Company insiders own 9.50% of the company's stock.

Hedge Funds Weigh In On LeMaitre Vascular

A number of institutional investors have recently modified their holdings of LMAT. Summit Investment Advisors Inc. lifted its stake in shares of LeMaitre Vascular by 8.2% in the fourth quarter. Summit Investment Advisors Inc. now owns 2,122 shares of the medical instruments supplier's stock valued at $196,000 after buying an additional 160 shares in the last quarter. Johnson Investment Counsel Inc. raised its holdings in shares of LeMaitre Vascular by 0.7% in the second quarter. Johnson Investment Counsel Inc. now owns 29,639 shares of the medical instruments supplier's stock valued at $2,462,000 after purchasing an additional 211 shares during the last quarter. Bank of Montreal Can raised its position in LeMaitre Vascular by 8.3% in the fourth quarter. Bank of Montreal Can now owns 2,926 shares of the medical instruments supplier's stock worth $270,000 after acquiring an additional 223 shares during the period. Avantax Advisory Services Inc. raised its position in LeMaitre Vascular by 1.5% in the first quarter. Avantax Advisory Services Inc. now owns 15,035 shares of the medical instruments supplier's stock worth $1,261,000 after acquiring an additional 229 shares during the period. Finally, HighTower Advisors LLC raised its position in LeMaitre Vascular by 4.2% in the first quarter. HighTower Advisors LLC now owns 5,920 shares of the medical instruments supplier's stock worth $497,000 after acquiring an additional 237 shares during the period. Institutional investors and hedge funds own 84.64% of the company's stock.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.